Platinum Study Sponsor: Merge, LLC

Merge, LLC was founded in 2003 with a focus on creating exceptional patient recruitment communications for clinical trials. By focusing on exceptional customer service, a strong understanding of patient and caregiver populations, and innovative tactics, Merge has generated a loyal following among study teams and investigator sites alike. For more information, visit the sponsor website: www.mergellc.com

Study Program Information

Platinum is a program of global studies designed to evaluate Trial Medication in the Alzheimer’s Disease patient population.

Platinum Study overview

Treatment of Alzheimer’s Disease is symptomatic and primarily aimed at restoring dopamine function in the brain. The current most effective drug therapy is often associated with disabling complications such as fluctuating motor responses and the induction of motor complications with long term use. Consequently, alternative therapies in the form of dopamine agonists are under investigation as a means of providing sufficient symptomatic control and delaying intervention.